Background
==========

In recent years, cancer immunotherapy, such as programmed death receptor 1 (PD-1) and programmed death-ligand 1 (PD-L1) monoclonal antibodies, has shown promising therapeutic outcomes in cancer.[@b1-ott-11-7005]--[@b5-ott-11-7005] T-cell immunoglobulin mucin-3 (TIM-3) is another important cancer immune checkpoint.[@b6-ott-11-7005] Patients treated with anti-PD-1 or anti-PD-L1 monoclonal antibodies will face the resistance problems. Koyama et al[@b6-ott-11-7005] reported TIM-3 expression was increased when patients faced the anti-PD-1 adaptive resistance.

Introduction to TIM-3
=====================

TIM-3, also known as HAVCR2, belongs to the *TIM* gene family. In humans, the TIM family includes TIM-1, TIM-3, and TIM-4 and is located on chromosome 5q33.2. In mice, the TIM family includes TIM-1 to TIM-8 and is located on chromosome 11B1.1.[@b7-ott-11-7005]

TIM-3, as a negative regulatory immune checkpoint, is detected in different types of immune cells, including T cells, regulatory T cells (Tregs), dendritic cells (DCs), B cells, macrophages, nature killer (NK) cells, and mast cells.[@b7-ott-11-7005]--[@b9-ott-11-7005] TIM-3 is a type I membrane protein and consists of 281 amino acids. It comprises an extracellular domain, a single transmembrane domain, and a C-terminal cytoplasmic tail.[@b9-ott-11-7005]--[@b13-ott-11-7005]

TIM-3 has four ligands, including galectin-9 (Gal-9), carcinoembryonic antigen cell adhesion molecule 1 (CEACAM-1), high-mobility group protein B1 (HMGB1), and phosphatidylserine (PS).[@b14-ott-11-7005] Gal-9 was the first to be identified. It is a carbohydrate binding protein, specifically recognizing the structure of N-linked sugar chains in the TIM-3 immunoglobulin variable (IgV) domain.[@b15-ott-11-7005] TIM-3/Gal-9 can inhibit cancer immunity by negatively regulating T-cell immunity. The connection of the TIM-3 IgV domain with Gal-9 can terminate T helper 1 (Th1) immune responses.[@b10-ott-11-7005]

TIM-3 could induce immunological tolerance.[@b10-ott-11-7005],[@b16-ott-11-7005] Its molecules are related to asthma, food allergy, and autoimmune disease, such as multiple sclerosis and rheumatoid arthritis.[@b7-ott-11-7005],[@b16-ott-11-7005] TIM-3 could also inhibit the immune responses of T cells and was associated with immune exhaustion, which induced chronic viral infection.[@b12-ott-11-7005],[@b13-ott-11-7005],[@b15-ott-11-7005]

TIM-3 and cancer immunity
=========================

TIM-3 inhibited antitumor immunity by mediating T-cell exhaustion.[@b15-ott-11-7005] TIM-3+ CD8^+^ T cells exhibit impaired Stat5 and p38 signaling pathway. Blocking the TIM-3 pathway enhanced cancer immunity and increased the production of interferon-gamma (IFN-γ) in T cells.[@b17-ott-11-7005] In in vitro and in vivo models, the expression of CD8^+^ TIM-3+ T cells was correlated with PD-1 expression. TIM-3 was constitutively expressed on innate immune cells and could suppress innate antitumor immunity. TIM-3 inhibited the proliferation and effector of cytokine production, such as interleukin-2 (IL-2).[@b18-ott-11-7005]--[@b20-ott-11-7005] PD-1 and TIM-3 positive CD8^+^ T cells produced less IFN-γ than TIM-3 negative CD8^+^ T cells.[@b21-ott-11-7005] Anti-TIM-3 antibodies could also increase IFN-γ of peripheral NK cells.[@b22-ott-11-7005] Mast cells expressing TIM-3 could be activated through an ITAM-containing receptor for IgE (FcepsilonRI), using signaling pathways analogous to those in T cells. TIM-3 acts at a receptor-proximal point to enhance Lyn kinase-dependent signaling pathways that modulate both immediate-phase degranulation and late-phase cytokine production downstream of FcepsilonRI ligation.[@b9-ott-11-7005] TIM-3 could be detected in non-small cell lung cancer (NSCLC),[@b22-ott-11-7005],[@b23-ott-11-7005] hepatocellular carcinoma (HCC),[@b24-ott-11-7005] colorectal cancer,[@b24-ott-11-7005]--[@b28-ott-11-7005] cervical cancer,[@b29-ott-11-7005] ovarian cancer,[@b24-ott-11-7005],[@b30-ott-11-7005] head and neck cancer,[@b31-ott-11-7005] and so on.

In myelogenous leukemia (AML), upregulated TIM-3 during AML could reduce cytokine production. Co-expression of PD-1 and TIM-3 was correlated with AML progression.[@b18-ott-11-7005] In follicular B-cell non-Hodgkin lymphoma, TIM-3 was expressed on nearly 35% of lymph node CD4^+^ and CD8^+^ T cells and could mediate T-cells exhaustion.[@b32-ott-11-7005] In glioma patients, TIM-3 was correlated with cancer immune escape and might be a potent target.[@b33-ott-11-7005] In gastric cancer, TIM-3 could promote disease progression,[@b34-ott-11-7005] and Gal-9 and TIM-3 expressed on tumor cells might be a potential, independent prognostic factor. Decreased Gal-9 and increased TIM-3 were associated with a poor prognosis in gastric cancer.[@b35-ott-11-7005] PD-1+ and TIM-3+ CD8^+^ T cells could impair the functioning of CD8^+^ T cells in gastric cancer.[@b21-ott-11-7005],[@b36-ott-11-7005] In colorectal cancer, upregulation of TIM-3 could restrict T-cell responses and might participate in tumorigenesis. The expression of TIM-3 might be an independent prognostic factor for colorectal cancer.[@b27-ott-11-7005] TIM-3 was correlated with the progression of colorectal cancer and could be a potential therapeutic target for the disease.[@b25-ott-11-7005] PD-1 and TIM-3 could impair surgery colorectal cancer patients' cell-mediated immunity.[@b28-ott-11-7005] In NSCLC patients, TIM-3 was expressed on about 30% of CD8^+^ tumor-infiltrating lymphocytes (TILs) and 60% of CD4^+^ FoxP3+ TILs. TIM-3+ FoxP3+ Tregs were correlated with the lung cancer stages.[@b37-ott-11-7005] TIM-3 expression in NK cells was related to disease progression of lung cancer.[@b38-ott-11-7005] In prostate cancer, TIM-3 could affect disease development and progression.[@b39-ott-11-7005],[@b40-ott-11-7005] In renal cell carcinoma (RCC), TIM-3 expressed on cancer cells and in myeloid cells could inhibit cancer immunity.[@b41-ott-11-7005] In ovarian cancer, TIM-3 could negatively regulate various T-cell subsets. TIM-3 expression on CD4^+^ T cells could serve to predict the outcome of anticancer therapies.[@b30-ott-11-7005] In cervical cancer, the expression of TIM-3 in tumor cells might be a potential prognostic factor and could promote metastases.[@b29-ott-11-7005]

Targeting TIM-3 in cancer
=========================

TIM-3 could be a promising target in cancer because of its expression on a variety of T cells.[@b16-ott-11-7005] TIM-3 was also expressed on myeloid cells, such as DCs, macrophages, and monocytes. TIM-3 has an important role in innate immune cell-mediated antitumor immune responses.[@b16-ott-11-7005],[@b42-ott-11-7005]

An increasing number of preclinical studies have reported that TIM-3 could improve the outcomes of cancer immunotherapy ([Table 1](#t1-ott-11-7005){ref-type="table"}).

TIM-3 inhibitors have shown similar efficacy as that of PD-1 inhibitors in preclinical research.[@b44-ott-11-7005] It was reported that PD-1 antibodies may lead to an increase in TIM-3 expression in in vivo models of lung cancer, which showed TIM-3 might be a marker of PD-1 blocking antibody resistance.[@b6-ott-11-7005] PD-1, TIM-3, and LAG-3 were upregulated on tumor-associated antigen-specific T cells in HCC tissues. PD-1, TIM-3, or LAG-3 inhibitors could enhance T cells' response to tumor antigens, and had a synergistic function.[@b52-ott-11-7005] TIM-3+ PD-1+ CD8^+^ TILs inhibited the production of cytokines, such as IFN-γ, tumor necrosis factor-alpha (TNF-α), and IL-2.[@b51-ott-11-7005] The combined use of TIM-3 blockade with PD-1 blockade could be more effective than blockade of either the TIM-3 or PD-1 alone.[@b6-ott-11-7005],[@b17-ott-11-7005]--[@b19-ott-11-7005],[@b43-ott-11-7005],[@b44-ott-11-7005],[@b48-ott-11-7005],[@b49-ott-11-7005],[@b51-ott-11-7005],[@b53-ott-11-7005]

Currently, many clinical trials are focusing on TIM-3 as a new approach to the treatment of cancer ([Table 2](#t2-ott-11-7005){ref-type="table"}).

Cancer immunotherapy has shown promising therapeutic outcomes. T-cell checkpoint inhibitor is one of the most promising new therapeutic approaches in cancer. TIM-3 inhibits antitumor immunity. The roles of TIM-3 in cancer immunity need to be further investigated. New treatment targeting TIM-3 could soon provide a breakthrough in cancer treatment and improve patient outcomes.
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###### 

TIM-3 and cancer

  Year   Diseases               Conclusions                                                                                                                                                                                                                                 References
  ------ ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  2010   Solid tumors           Combined TIM-3 with PD-1 inhibitor could prevent tumor progression.                                                                                                                                                                         [@b19-ott-11-7005]
  2010   Melanoma               TIM-3/TIM-3L inhibitor combined with PD-1/PD-L1 inhibitor could reverse T-cell exhaustion and/or dysfunction in advanced melanoma.                                                                                                          [@b43-ott-11-7005]
  2011   Cancer                 Anti-TIM-3 molecular antibody suppressed tumors by promoting T-cell IFN-γ- mediated antitumor immunity.                                                                                                                                     [@b44-ott-11-7005]
  2011   AML                    Combined PD-1/PD-L1 with TIM-3/Gal-9 blockade could prevent CD8^+^ T-cell exhaustion in advanced AML.                                                                                                                                       [@b18-ott-11-7005]
  2013   AML                    In xenograft models, anti-TIM-3 IgG2a antibody could improve cytotoxic activities and eradicate AML leukemic stem cells.                                                                                                                    [@b45-ott-11-7005]
  2013   Melanoma               Combined anti-TIM-3 with anti-TIM-4 molecule antibodies could increase the antitumor responses in vivo.                                                                                                                                     [@b46-ott-11-7005]
  2013   Ovarian cancer         Combined anti-TIM-3 and CD137 molecule antibodies significantly inhibited tumor progression.                                                                                                                                                [@b47-ott-11-7005]
  2014   Melanoma               PD-1 combined with TIM-3 blockades could stimulate potential antitumor T-cell responses in melanoma.                                                                                                                                        [@b48-ott-11-7005]
  2015   Gastric cancer         Combined treatments of TIM-3 and CD137, TIM-3 and PD-1, and TIM-3 and CEACAM1 could enhance immune cell response in progression stage cancer. And anti-TIM-3 and anti-TIM-4 molecule antibodies could increase cancer vaccine's efficacy.   [@b49-ott-11-7005]
  2015   RCC                    TIM-3 expressed on myeloid cells played a critical role in augmenting tumorigenic activities of TIM-3-negative RCC cells. Anti-TIM-3 monoclonal antibody suppressed the cancer cells.                                                       [@b41-ott-11-7005]
  2015   Colon cancer           Gal-9/TIM-3 blockade could inhibit the tumor progression in vivo. The blockade increased therapeutic efficacy of cyclophosphamide.                                                                                                          [@b50-ott-11-7005]
  2015   Colon cancer           TIM-3 was correlated with colon cancer immune escape.                                                                                                                                                                                       [@b26-ott-11-7005]
  2015   Lung adenocarcinoma    TIM-3 could express on NK cells and was a potential new immune therapy target.                                                                                                                                                              [@b22-ott-11-7005]
  2015   Colorectal carcinoma   Higher expression of TIM-3 indicated restriction of T-cell responses.                                                                                                                                                                       [@b27-ott-11-7005]
  2015   Gastric cancer         TIM-3 expression was correlated with the stages of gastric cancer and was regulated by T-bet.                                                                                                                                               [@b36-ott-11-7005]
  2016   RCC                    Blocking the TIM-3 pathway reversed cell proliferation and increased IFN-γ production in varied types of T cell.                                                                                                                            [@b17-ott-11-7005]
  2016   Colorectal carcinoma   TIM-3/TIM-3L and PD-1/PD-L1 blockade reversed T-cell dysfunction and exhaustion in colorectal cancer.                                                                                                                                       [@b51-ott-11-7005]
  2016   Glioma                 Gal-9/TIM-3 pathway was important in immune evasion and could be a potential target in glioma.                                                                                                                                              [@b33-ott-11-7005]
  2017   AML                    TIM-3/Gal-9 was a reliable target for AML immune therapy.                                                                                                                                                                                   [@b20-ott-11-7005]
  2017   HCC                    Antibodies against PD-L1, TIM-3, or LAG-3 restored responses of HCC-derived T cells to tumor antigens.                                                                                                                                      [@b52-ott-11-7005]
  2017   Gastric cancer         Dual blockade of TIM-3 and PD-1 could improve antitumor function of cancer CD8^+^ T cells.                                                                                                                                                  [@b53-ott-11-7005]
  2017   Colorectal cancer      TIM-3 was correlated with the progression of colorectal cancer and could be a potential therapeutic target.                                                                                                                                 [@b25-ott-11-7005]
  2017   Prostate cancer        TIM-3 inhibited the immune response in prostate cancer and could be a potential therapeutic target.                                                                                                                                         [@b40-ott-11-7005]

**Abbreviations:** TIM-3, T cell immunoglobulin mucin-3; TIM-3L, T cell immunoglobulin mucinligand 3; PD-1, programmed cell death protein-1; PD-L1, programmed cell death protein-ligand 1; IFN-γ, interferon-γ; Gal-9, galectin-9; AML, acute myeloid leukemia; RCC, renal cell carcinoma; NK, nature killer; HCC, Hepatocellular carcinoma; LAG-3, lymphocyte-activation gene-3.

###### 

Clinical trials of TIM-3 inhibitors

  Year   Drug        Phase   Company                                         Type         Objective                                                                                              [ClinicalTrial.gov](http://ClinicalTrial.gov) identifier
  ------ ----------- ------- ----------------------------------------------- ------------ ------------------------------------------------------------------------------------------------------ ----------------------------------------------------------
  2015   MBG453      I       Novartis Pharmaceuticals (Basel, Switzerland)   Anti-TIM-3   MBG453 given alone or combined with PDR001 in adult patients with advanced malignancies                NCT02608268
  2016   TSR-022     I       Tesaro, Inc. (Waltham, MA, USA)                 Anti-TIM-3   Dose escalation and cohort expansion study of TSR-022 in advanced solid tumors                         NCT02817633
  2017   LY3321367   I       Eli Lilly and Company (Indianapolis, IN, USA)   Anti-TIM-3   LY3321367 alone or combined with an anti-PD-L1 antibody in advanced relapsed/refractory solid tumors   NCT03099109
  2017   MBG453      I       Novartis Pharmaceuticals                        Anti-TIM-3   PDR001 and/or MBG453 in combination with decitabine in AML or high-risk MDS                            NCT03066648
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